Introducing a new vaccination program in a country has become a complex process with multiple decision makers participating. The decision makers may consider the new vaccination program from different perspectives and could therefore be interested in different measures of economic value. These measures include the value for money, affordability and the net present value of the investment. The ISPOR Task Force on the Economic Evaluation of Vaccines for Infectious Diseases has selected three methods currently being used to assess the value of new vaccination programs (cost-effectiveness analysis, partial optimization modelling, and fiscal modelling). At this forum, a proposed set of guidelines (perspective, comparator, time horizon, discounting, model structure, data requirements, outcome measures, uncertainty evaluation, validation, and transparency) for each of these methods as well as recommendations of how they can be extended beyond a focus on individual health outcomes to include a broader set of outcomes for the person vaccinated, the household and the community will be presented. Forum participants will be asked to give the task force feedback on the proposed guidelines for the traditional and extended value assessments.